DER1.1 Antibody

What is the biological function of DERL1/Derlin-1 protein?

DERL1/Derlin-1 functions as a critical component of endoplasmic reticulum-associated degradation (ERAD) for misfolded luminal proteins. The protein forms homotetramers that encircle large channels traversing the endoplasmic reticulum (ER) membrane, facilitating retrotranslocation of misfolded proteins from the ER into the cytosol where they undergo ubiquitination and subsequent proteasomal degradation. The channel contains a lateral gate within the membrane providing direct access to membrane proteins without requiring reentry into the ER lumen. Additionally, DERL1/Derlin-1 may mediate interactions between VCP and misfolded proteins, and plays a role in ER stress-induced pre-emptive quality control by selectively attenuating the translocation of newly synthesized proteins into the ER and rerouting them to the cytosol for proteasomal degradation .

What are the known alternative names for DERL1/Derlin-1?

The DERL1/Derlin-1 protein is known by several alternative names in the scientific literature, including:

• DER1

• UNQ243/PRO276

• DERL1

• Degradation in endoplasmic reticulum protein 1

• Der1-like protein 1

• DERtrin-1

• DER-1

• FLJ13784

• FLJ42092

• MGC3067

• PRO2577

What is the typical molecular weight of DERL1/Derlin-1 protein?

DERL1/Derlin-1 protein has an expected molecular mass of approximately 22-28.8 kDa, with reported variations due to post-translational modifications. In western blot applications, the protein typically appears as a band at approximately 22 kDa, though this may vary slightly depending on the specific antibody used and sample preparation methods .

What are the validated applications for DERL1/Derlin-1 antibodies?

Based on the available literature and product information, DERL1/Derlin-1 antibodies have been validated for multiple experimental applications:

Researchers should validate these applications for their specific experimental conditions and antibody source .

How should samples be prepared for optimal DERL1/Derlin-1 detection in western blotting?

For optimal detection of DERL1/Derlin-1 in western blotting, researchers should follow these methodological guidelines:

• Sample preparation:

  • For cell lysates: Use RIPA buffer containing protease inhibitors

  • For tissue samples: Homogenize in RIPA buffer with protease inhibitors using a tissue homogenizer

• Membrane preparation:

  • Since DERL1/Derlin-1 is a multi-pass membrane protein, perform alkaline fractionation of microsomal samples

  • Evaluate detergent extraction carefully as demonstrated in studies of immature endosperm

• Protein separation:

  • Use 12-15% SDS-PAGE gels due to the relatively low molecular weight of the protein

  • Load 20-50 μg of total protein per lane depending on expression levels

• Transfer conditions:

  • Semi-dry or wet transfer at 100V for 60-90 minutes

  • Use PVDF membranes for better retention of low molecular weight proteins

• Blocking and antibody incubation:

  • Block with 5% non-fat dry milk in TBST for 1 hour at room temperature

  • Incubate with primary antibody (typically 1:1000 dilution) overnight at 4°C

  • Wash thoroughly with TBST before applying appropriate secondary antibody

How can researchers validate the specificity of DERL1/Derlin-1 antibodies?

Validating antibody specificity is crucial for reliable research outcomes. For DERL1/Derlin-1 antibodies, researchers should implement these validation strategies:

• Positive and negative controls:

  • Use cell lines known to express DERL1/Derlin-1 (positive control)

  • Use DERL1 knockout or knockdown samples as negative controls

• Peptide competition assay:

  • Pre-incubate the antibody with excess immunizing peptide

  • Compare staining/detection patterns with and without peptide competition

• Multiple antibody approach:

  • Use antibodies raised against different epitopes of DERL1/Derlin-1

  • Confirm consistent staining patterns across different antibodies

• Orthogonal techniques:

  • Correlate protein detection with mRNA expression (qPCR)

  • Confirm subcellular localization using fractionation experiments

• Immunoprecipitation followed by mass spectrometry:

  • Perform IP with the antibody and confirm target identity by MS analysis

How can DERL1/Derlin-1 antibodies be used to study ERAD pathway dynamics?

Studying ERAD pathway dynamics using DERL1/Derlin-1 antibodies requires sophisticated experimental approaches:

• Co-immunoprecipitation studies:

  • Use DERL1/Derlin-1 antibodies to pull down protein complexes

  • Analyze interactions with other ERAD components such as VCP/p97, ubiquitin ligases, and substrate proteins

  • Compare complex formation under normal versus ER stress conditions

• Proximity labeling approaches:

  • Combine antibody-based detection with BioID or APEX2 proximity labeling

  • Identify transient interaction partners during ERAD processes

• Live-cell imaging:

  • Use fluorescently tagged anti-DERL1 antibody fragments (Fabs) for dynamic studies

  • Track DERL1/Derlin-1 clustering during ERAD activation

• ERAD substrate flux analysis:

  • Employ pulse-chase experiments with DERL1/Derlin-1 immunoprecipitation

  • Quantify substrate association and dissociation rates during degradation

• Structural studies:

  • Utilize antibodies to stabilize DERL1/Derlin-1 homotetramers for cryo-EM analysis

  • Map channel formation and structural changes during substrate processing

What are the considerations for studying DERL1/Derlin-1 involvement in viral immune evasion?

DERL1/Derlin-1 plays critical roles in viral immune evasion, particularly with cytomegaloviruses. When investigating these mechanisms:

• Viral protein interaction studies:

  • Use co-immunoprecipitation with DERL1/Derlin-1 antibodies to capture viral proteins like US11

  • Employ proximity ligation assays to confirm interactions in intact cells

• MHC class I degradation analysis:

  • Monitor MHC class I heavy chain degradation in virus-infected versus uninfected cells

  • Use DERL1/Derlin-1 antibodies to assess recruitment to degradation complexes

• Reconstitution experiments:

  • Perform DERL1/Derlin-1 knockdown/knockout followed by rescue with mutant forms

  • Identify critical domains for viral protein interactions

• Temporal dynamics:

  • Analyze the sequential recruitment of DERL1/Derlin-1 to viral protein complexes

  • Study the kinetics of MHC class I degradation pathways

• Inhibitor studies:

  • Use specific inhibitors of DERL1/Derlin-1 function to assess impact on viral immune evasion

  • Compare results with antibody-mediated blockade of DERL1/Derlin-1 function

How can researchers differentiate between distinct DERL1/Derlin-1 functional complexes?

DERL1/Derlin-1 participates in multiple functional complexes with distinct compositions and roles. To differentiate between these complexes:

• Blue native PAGE combined with antibody detection:

  • Preserve native protein complexes through gentle solubilization

  • Use DERL1/Derlin-1 antibodies for western blot detection after native separation

  • Identify distinct high-molecular-weight complexes

• Sequential immunoprecipitation:

  • First immunoprecipitate with DERL1/Derlin-1 antibodies

  • Subsequently immunoprecipitate with antibodies against suspected complex components

  • Analyze the composition of different subcomplexes

• Glycerol gradient fractionation:

  • Separate protein complexes based on size and density

  • Detect DERL1/Derlin-1 distribution across fractions

  • Correlate with distribution of other ERAD components

• Cross-linking mass spectrometry:

  • Stabilize protein interactions with chemical cross-linkers

  • Immunoprecipitate DERL1/Derlin-1 complexes

  • Analyze by mass spectrometry to identify interaction interfaces

• Super-resolution microscopy:

  • Use fluorescently labeled DERL1/Derlin-1 antibodies

  • Perform STORM or PALM imaging to visualize distinct complex formations

  • Quantify colocalization with other ERAD components

What are common pitfalls when interpreting DERL1/Derlin-1 antibody results, and how can they be addressed?

Researchers commonly encounter several pitfalls when working with DERL1/Derlin-1 antibodies:

Addressing these issues requires rigorous controls and methodological optimization specific to each experimental system .

How should researchers interpret conflicting results between different DERL1/Derlin-1 antibodies?

When faced with conflicting results from different DERL1/Derlin-1 antibodies, researchers should follow this systematic analysis approach:

• Epitope mapping comparison:

  • Identify the specific epitopes recognized by each antibody

  • Assess whether epitopes might be differentially accessible in various experimental conditions

  • Consider whether post-translational modifications might affect epitope recognition

• Antibody validation status review:

  • Examine the validation data for each antibody (knockout controls, peptide competition, etc.)

  • Consider the applications for which each antibody has been validated

  • Evaluate the citation history and independent validation reports

• Experimental condition analysis:

  • Compare sample preparation methods, buffers, and detection systems

  • Assess whether differences in protein conformation might affect antibody binding

  • Test whether denaturation conditions influence epitope accessibility

• Orthogonal approach implementation:

  • Use non-antibody methods (mass spectrometry, CRISPR/Cas9 tagging) to resolve conflicts

  • Compare with mRNA expression patterns

  • Consider genetic approaches (overexpression, knockdown) to validate findings

• Contextual interpretation:

  • Consider whether observed differences reflect biological reality (different complexes, conformations)

  • Document conditions under which each antibody yields reproducible results

  • Report all findings transparently, including discrepancies

How can DERL1/Derlin-1 antibodies be used in cancer research?

DERL1/Derlin-1 antibodies offer several valuable applications in cancer research based on emerging evidence of its role in cancer biology:

• Expression profiling in tumor samples:

  • Use immunohistochemistry with DERL1/Derlin-1 antibodies to assess expression in tissue microarrays

  • Correlate expression levels with clinical outcomes and treatment responses

  • Develop prognostic biomarker applications

• ER stress response analysis:

  • Investigate DERL1/Derlin-1 upregulation during ER stress in cancer cells

  • Study how DERL1/Derlin-1-mediated ERAD contributes to cancer cell survival

  • Target ERAD pathways for therapeutic intervention

• IGF1R signaling studies:

  • Examine how DERL1/Derlin-1 regulates IGF1R receptor levels in cancer

  • Investigate potential for combined targeting of DERL1/Derlin-1 and IGF1R pathways

  • Assess impact on downstream oncogenic signaling

• Therapeutic resistance mechanisms:

  • Study DERL1/Derlin-1 involvement in handling misfolded proteins after chemotherapy

  • Investigate correlations between DERL1/Derlin-1 expression and drug resistance

  • Develop strategies to modulate ERAD activity to enhance therapy efficacy

• Development of targeted therapies:

  • Use antibodies to identify cancer-specific DERL1/Derlin-1 complexes

  • Develop antibody-drug conjugates targeting cancer cells with high DERL1/Derlin-1 expression

  • Design inhibitors that disrupt specific DERL1/Derlin-1 interactions in cancer cells

What novel approaches are being developed to study DERL1/Derlin-1 channel structure and function?

Recent advances in structural biology and imaging technologies offer new opportunities for studying DERL1/Derlin-1 channel structure and function:

• Cryo-electron microscopy approaches:

  • Use antibody fragments to stabilize DERL1/Derlin-1 homotetramers for structural analysis

  • Investigate the structural basis of channel gating and substrate recognition

  • Map interaction interfaces with other ERAD components

• Single-molecule tracking:

  • Employ fluorescently labeled antibody fragments for live-cell imaging

  • Track the dynamics of individual DERL1/Derlin-1 channels during substrate processing

  • Quantify dwell times and diffusion coefficients under various conditions

• In vitro reconstitution systems:

  • Purify DERL1/Derlin-1 using antibody-based affinity chromatography

  • Reconstitute functional channels in artificial membrane systems

  • Measure channel conductance and substrate translocation in controlled environments

• Computational modeling with experimental validation:

  • Use antibody-derived structural constraints to inform molecular dynamics simulations

  • Predict channel conformational changes during substrate processing

  • Validate predictions using antibody-based accessibility assays

• CRISPR-based gene editing combined with antibody detection:

  • Introduce specific mutations in endogenous DERL1/Derlin-1

  • Use antibodies to assess effects on channel assembly and function

  • Correlate structural alterations with functional outcomes

How might deep learning approaches enhance antibody design for studying DERL1/Derlin-1?

Deep learning technologies are transforming antibody development and could significantly impact DERL1/Derlin-1 research:

• Computationally designed antibody libraries:

  • Train deep learning models on existing antibody sequence data

  • Generate novel antibody variable regions with high humanness and developability

  • Screen in silico for epitopes specific to DERL1/Derlin-1 but not other Derlin family members

• Epitope-specific antibody design:

  • Use structural predictions to identify accessible, unique regions of DERL1/Derlin-1

  • Design antibodies targeting conformational states specific to different functional complexes

  • Generate antibodies distinguishing between monomeric and tetrameric forms

• Function-modulating antibody development:

  • Design antibodies that specifically block channel function without affecting complex formation

  • Create antibodies that selectively disrupt interactions with viral proteins

  • Develop antibodies that stabilize specific conformational states for structural studies

• Experimental validation strategies:

  • Produce a diverse panel of computationally designed antibodies

  • Validate binding specificity, affinity, and effects on DERL1/Derlin-1 function

  • Compare performance with traditionally developed antibodies

Recent research demonstrates that deep learning-based antibody design can produce sequences with favorable developability profiles, high expression levels, thermal stability, and low self-association - properties essential for effective research reagents targeting complex membrane proteins like DERL1/Derlin-1 .

What strategies can overcome challenges in detecting DERL1/Derlin-1 in specific tissues or cell types?

Detection of DERL1/Derlin-1 in certain tissues or cell types can be challenging due to expression levels, tissue composition, or technical limitations. Researchers can employ these specialized approaches:

• Signal amplification methods:

  • Implement tyramide signal amplification for IHC/ICC applications

  • Use polymer-based detection systems with enhanced sensitivity

  • Consider proximity ligation assays for detecting DERL1/Derlin-1 in specific complexes

• Tissue-specific protocol optimization:

  • Adjust fixation conditions based on tissue type (formalin time, embedding protocols)

  • Optimize antigen retrieval methods (heat-induced versus enzymatic)

  • Develop tissue-specific blocking strategies to reduce background

• Sample enrichment techniques:

  • Perform subcellular fractionation to concentrate ER membranes

  • Use laser capture microdissection for specific cell populations

  • Implement cell sorting for heterogeneous samples

• Antibody format adaptation:

  • Use directly conjugated primary antibodies to eliminate secondary detection issues

  • Employ antibody fragments (Fab, F(ab')2) for better tissue penetration

  • Consider using alternative isotypes to reduce tissue-specific background

• Multiplexed detection strategies:

  • Combine DERL1/Derlin-1 detection with markers of ER stress or ERAD activation

  • Use spectral unmixing for simultaneous detection of multiple targets

  • Implement sequential staining protocols for co-localization studies

How can researchers effectively study DERL1/Derlin-1 dynamics during cellular stress responses?

Analyzing DERL1/Derlin-1 during cellular stress responses requires specialized techniques:

• Time-course experiments with synchronized stress induction:

  • Apply ER stressors (tunicamycin, thapsigargin) at defined intervals

  • Collect samples at multiple time points for western blotting and microscopy

  • Use DERL1/Derlin-1 antibodies to track changes in expression, localization, and complex formation

• Live-cell imaging approaches:

  • Use cell-permeable fluorescently tagged antibody fragments

  • Track DERL1/Derlin-1 redistribution during stress response

  • Correlate with markers of ER stress (XBP1 splicing reporters, ATF6 translocation)

• Quantitative interaction analysis:

  • Perform co-immunoprecipitation with DERL1/Derlin-1 antibodies before and during stress

  • Quantify changes in interaction partners using mass spectrometry

  • Validate key interactions with reciprocal co-immunoprecipitation

• Functional readouts:

  • Measure ERAD substrate degradation rates using pulse-chase analysis

  • Assess contribution of DERL1/Derlin-1 using antibody-based inhibition approaches

  • Correlate DERL1/Derlin-1 complex formation with ERAD efficiency

• Integration with UPR signaling:

  • Monitor parallel activation of UPR sensors (IRE1, PERK, ATF6)

  • Assess how DERL1/Derlin-1 function modulates these pathways

  • Use antibodies against phosphorylated forms of stress sensors for pathway analysis

What considerations are important when using DERL1/Derlin-1 antibodies in disease models?

When applying DERL1/Derlin-1 antibodies in disease models, researchers should consider these specialized approaches:

• Model-specific validation:

  • Validate antibody specificity in each disease model system

  • Compare staining patterns between healthy and diseased tissues

  • Confirm epitope accessibility in pathological samples

• Context-dependent expression analysis:

  • Assess changes in DERL1/Derlin-1 expression levels during disease progression

  • Correlate with markers of ER stress (BiP/GRP78, CHOP, XBP1s)

  • Determine whether disease-associated mutations affect antibody recognition

• Therapeutic intervention monitoring:

  • Use DERL1/Derlin-1 antibodies to track changes after treatment

  • Assess whether ERAD function normalization correlates with clinical improvement

  • Develop antibody-based imaging approaches for in vivo monitoring

• Human-animal model comparisons:

  • Validate antibody cross-reactivity between species

  • Compare DERL1/Derlin-1 expression patterns in human samples and animal models

  • Assess whether disease-associated changes are conserved across species

• Integration with other disease biomarkers:

  • Correlate DERL1/Derlin-1 levels with established disease markers

  • Develop multiplexed detection approaches for comprehensive profiling

  • Assess potential as a prognostic or predictive biomarker

How do monoclonal and polyclonal DERL1/Derlin-1 antibodies compare in research applications?

Understanding the relative advantages of different antibody types is essential for selecting the optimal reagent:

Selection should be based on specific experimental requirements and validated for each application .

What approaches can researchers use to validate potentially cross-reactive DERL1/Derlin-1 antibodies?

Given the sequence homology between Derlin family members, validation of antibody specificity is crucial:

• Recombinant protein panel testing:

  • Test antibody reactivity against all purified Derlin family proteins

  • Determine cross-reactivity profiles and relative affinities

  • Identify conditions that maximize specificity

• Genetic knockout/knockdown controls:

  • Use CRISPR/Cas9 to generate DERL1 knockout cell lines

  • Perform siRNA-mediated knockdown of individual Derlin family members

  • Validate antibody specificity by testing detection in these systems

• Epitope competition assays:

  • Design peptides specific to unique regions of each Derlin family member

  • Perform competition experiments to identify antibody binding specificity

  • Map specific recognition determinants for each antibody

• Orthogonal detection methods:

  • Compare antibody-based detection with targeted mass spectrometry

  • Use RNA-seq or qPCR to correlate protein detection with mRNA levels

  • Implement CRISPR-based tagging to validate endogenous protein detection

• Cross-species validation:

  • Test antibody reactivity against Derlin homologs from different species

  • Leverage sequence differences between species to map specificity determinants

  • Use evolutionary conservation patterns to predict cross-reactivity

How can DERL1/Derlin-1 antibodies contribute to understanding disease mechanisms?

DERL1/Derlin-1 antibodies can provide valuable insights into disease mechanisms across several pathological conditions:

• Neurodegenerative diseases:

  • Analyze DERL1/Derlin-1 expression and localization in Alzheimer's and Parkinson's disease tissues

  • Investigate correlations between DERL1/Derlin-1 function and protein aggregation

  • Assess potential protective roles in clearing misfolded proteins

• Cancer biology:

  • Examine DERL1/Derlin-1 expression in tumor progression using tissue microarrays

  • Correlate with markers of ER stress and UPR activation

  • Investigate potential as prognostic biomarker or therapeutic target

• Viral infection mechanisms:

  • Study how viruses manipulate DERL1/Derlin-1 to evade immune surveillance

  • Analyze MHC class I degradation pathways during infection

  • Develop strategies to block viral subversion of ERAD

• Metabolic disorders:

  • Investigate DERL1/Derlin-1 involvement in insulin receptor processing

  • Study links between ERAD dysfunction and metabolic disease

  • Examine potential therapeutic targeting of specific ERAD pathways

• Inflammatory conditions:

  • Analyze how ER stress and DERL1/Derlin-1 function influence inflammatory signaling

  • Correlate with inflammatory biomarkers and disease activity

  • Explore DERL1/Derlin-1 as a potential therapeutic target for inflammatory disorders

What role might DERL1/Derlin-1 play in immune checkpoint inhibitor research?

Recent research has suggested potential links between ERAD pathways and immune checkpoint regulation:

• PD-1/PD-L1 pathway interactions:

  • Investigate potential role of DERL1/Derlin-1 in regulating PD-1/PD-L1 protein levels

  • Study whether ERAD dysfunction affects checkpoint inhibitor efficacy

  • Use DERL1/Derlin-1 antibodies to track protein during checkpoint inhibitor therapy

• Patient stratification biomarker development:

  • Analyze DERL1/Derlin-1 expression in responders versus non-responders to therapy

  • Correlate with CD4/CD8 ratios and other immune parameters

  • Develop predictive biomarker panels including DERL1/Derlin-1

• Immune-related adverse event mechanisms:

  • Study DERL1/Derlin-1 expression in tissues affected by immune-related adverse events

  • Investigate links between ER stress, ERAD function, and autoimmune-like toxicities

  • Use antibodies to track changes during development and resolution of toxicity

• Combination therapy approaches:

  • Explore targeting DERL1/Derlin-1 function alongside checkpoint inhibitor therapy

  • Develop strategies to enhance antigen presentation through ERAD modulation

  • Use antibodies to monitor pathway modulation during experimental combination therapy

The increasing understanding of how PD-1 receptor occupancy on CD4+ T cells relates to immune-related adverse events suggests potential links with ER protein quality control pathways that merit further investigation .